OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Crohns & Colitis is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
P470 Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients	460
DOP59 Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore	250
P572 Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it’s time to make iron deficiency part of tight monitoring to reach T2T? – preliminary r	212
P554 Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?	116
P588 Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients	103
P678 Definition of a microbial signature as a predictor of post-surgical recurrence in patients with Crohn’s disease	100
P664 Bidirectional association between inflammatory bowel disease and psoriasis in a pediatric population: A nationwide insurance claim data analysis in South Korea	91
P622 Comparison of midterm outcomes in Pediatric Crohn’s Disease patients treated with either Exclusive Enteral Nutrition or Corticosteroids around disease diagnosis– a population based study	86
P135 Proximal Extension of lower rectal Ulcerative Proctitis	84
P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice	67
P574 Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study	66
DOP87 Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s Disease	63
DOP35 Ambulatory care management of 70 patients with Acute Severe Ulcerative Colitis in comparison to 700 inpatients: Insights from a multicentre UK cohort study	60
P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease	57
P350 SAFIIR: Study of Anemia Following Intravenous Iron Repletion	57
P404 Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany	50
P175 Low relapse rates after biologic therapy discontinuation in a large real life cohort of IBD patients with initial severe disease: do biologics alter the natural history of disease?	49
P659 Colonoscopic screening of symptomatic patients suggests an emerging inflammatory bowel disease (IBD) in urban and rural south India	48
P341 Fracture risk in middle-age and older patients with inflammatory bowel disease: A Korean nationwide population-based cohort study	47
P518 Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID	46
P719 Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection	45
P708 Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosa	45
P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease	43
P452 Oral ciclosporin is a convenient, effective and safe rescue therapy in steroid refractory Acute Severe Ulcerative Colitis: A single tertiary centre experience	42
P697 Examining the regulatory role of epigenetic and transcriptomic alterations in anti-TNFα treatment response and disease progression in patients with Ulcerative Colitis	40

P466 Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab	39
P513 Treatment persistence in bio-naive patients with long-standing Crohn’s disease treated with first-line biologics: real-life data from a Croatian tertiary center	39
OP07 Artificial intelligence surpasses gastrointestinal experts in the classification of endoscopic severity among Ulcerative Colitis	38
Mass-Cytometry-Based Quantification of Global Histone Post-Translational Modifications at Single-Cell Resolution Across Peripheral Immune Cells in IBD	37
Keeping It Simple: Using Intestinal Ultrasound to Assess Ulcerative Colitis with a Novel UC-Ultrasound Index	36
Inequitable Access to IBD Therapies Extends Beyond Developing Nations	36
P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study	36
P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission	36
P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts	34
P354 Early treatment versus active surveillance after ileocolic resection in Crohn’s disease: a retrospective cohort study	34